GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being
developed for the treatment of chronic HCV infection. This Phase II, multicenter,
parallel-group, randomized, dose-ranging study will assess the safety and tolerability,
antiviral activity, and pharmacokinetics of GSK2336805 at 2 dose levels (40 and 60 mg) in
combination with pegylated interferon alfa-2a (PEG) and ribavirin (RIBA) in approximately 100
treatment-naïve subjects with chronic genotype 1 HCV infection.
In a separate nonrandomized single-arm cohort, up to 15 treatment-naïve subjects with
genotype 4 chronic HCV infection will be enrolled in parallel at the dose level of 60 mg of
GSK2336805.